126 293

Cited 11 times in

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.

DC Field Value Language
dc.contributor.authorJin, YJ-
dc.contributor.authorLee, JW-
dc.contributor.authorLee, JI-
dc.contributor.authorPark, SH-
dc.contributor.authorPark, CK-
dc.contributor.authorKim, YS-
dc.contributor.authorJeong, SH-
dc.contributor.authorKim, JH-
dc.contributor.authorHwang, SG-
dc.contributor.authorRim, KS-
dc.contributor.authorYim, HJ-
dc.contributor.authorCheong, JY-
dc.contributor.authorCho, SW-
dc.contributor.authorLee, JS-
dc.contributor.authorPark, YM-
dc.contributor.authorJang, JW-
dc.contributor.authorLee, CK-
dc.contributor.authorSohn, JH-
dc.contributor.authorYang, JM-
dc.contributor.authorHan, S-
dc.date.accessioned2014-05-15-
dc.date.available2014-05-15-
dc.date.issued2013-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/9955-
dc.description.abstractBACKGROUND: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).



METHODS: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.



RESULTS: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7 × 10(5) and >7 × 10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.



CONCLUSIONS: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
-
dc.language.isoen-
dc.subject.MESHAntiviral Agents/adverse effects/*therapeutic use-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHepacivirus/genetics-
dc.subject.MESHHepatitis C, Chronic/*drug therapy/virology-
dc.subject.MESHHumans-
dc.subject.MESHInterferon-alpha/adverse effects/*therapeutic use-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPolyethylene Glycols/adverse effects/*therapeutic use-
dc.subject.MESHRecombinant Proteins/adverse effects/therapeutic use-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRibavirin/therapeutic use-
dc.subject.MESHViral Load-
dc.titleMulticenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.-
dc.typeArticle-
dc.identifier.pmid23627926-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644280/-
dc.contributor.affiliatedAuthor정, 재연-
dc.contributor.affiliatedAuthor조, 성원-
dc.type.localJournal Papers-
dc.identifier.doi10.1186/1471-230X-13-74-
dc.citation.titleBMC gastroenterology-
dc.citation.volume13-
dc.citation.date2013-
dc.citation.startPage74-
dc.citation.endPage74-
dc.identifier.bibliographicCitationBMC gastroenterology, 13:74-74, 2013-
dc.identifier.eissn1471-230X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Files in This Item:
23627926.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse